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Abstract
Background: Asthma is the most common chronic disease in childhood and places a significant burden on
public and private health systems. This retrospective cohort analysis utilised administrative healthcare claims
data (US Clinformatics™ Multiplan database; compliant with the US Department of Health & Human Services
Health Insurance Portability and Accountability Act) to characterise asthma exacerbations requiring
intervention in a US paediatric patient population.
Methods: Patients aged > 1–17 years with a recorded asthma diagnosis and receiving treatment were identified in
the US Clinformatics™ Multiplan database over a 9-year period (2004–2012). Both incident and prevalent cases of
asthma were included, with the most recently recorded asthma diagnosis designated as the index date. The 12-month
period following the index date was analysed for asthma exacerbations, defined as an event requiring treatment with
systemic corticosteroid or resulting in an asthma-related hospitalisation or emergency department visit.
Results: Data from 734,114 children with asthma (41.5 % females, 58.5 % males) were analysed, of this cohort 34.4 %
experienced≥ 1 exacerbation during the follow-up period. The proportion who experienced≥ 1 exacerbation
increased from 28.9 % in 2004 to 36.3 % in 2012, based on the reported index date. Their mean annual exacerbation
frequency was 1.4; 85.8 % of exacerbations were defined by systemic corticosteroids use. A consistent trend of
increased exacerbation incidence in the fall and early winter was observed, in particular exacerbations defined by
systemic corticosteroid use. A greater proportion of asthma-related hospitalisations were associated with younger age.
Conclusions: Approximately one-third of children experienced≥ 1 exacerbation in real-world clinical practice. A
targeted treatment approach with a focus on those with a history of recurrent exacerbations is recommended to
improve asthma control. This targeted approach could also minimise the frequent systemic corticosteroid exposure
particularly at an early age when side effects of systemic corticosteroids are more pronounced.
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Background
Asthma has been estimated to affect up to 10 % of
children in the US [1]. Furthermore, the prevalence of
uncontrolled asthma in children remains high despite
widespread availabilityy of effective controller medica-
tions [2–5]. Lack of adherence to maintenance therapies
such as inhaled corticosteroids, may lead to poor asthma
control, particularly in older children [6]. Poor asthma
control is associated with increased frequency of exacer-
bations [7, 8] and consequent hospitalisation [2]. In view
of the high prevalence of uncontrolled asthma, and
considering the impact of exacerbations on patients in
terms of reduced quality of life and lost school days [9],
and on healthcare costs [10], improving the diagnosis
and management of paediatric asthma is a high public
health priority.
Asthma exacerbations are acute worsening of symptoms
that often require treatment with systemic corticosteroids,
visits to the emergency department (ED), or hospital
admission [11]. Exacerbations are closely associated with
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asthma-related morbidity and mortality and are respon-
sible for considerable healthcare costs [10]. Children
account for approximately one third of all asthma-related
hospitalisations [12]. Despite improvements in asthma
management and advances in therapeutics, there has not
been a reduction in the reported incidence of exacerba-
tions in paediatric asthma [5]. Previously reported findings
from controlled clinical trials indicate that asthma exacer-
bations in children [9, 13], as well as in adults [14, 15], are
predictive of future exacerbations. However, data from
randomised controlled trials are often not representative
of real-world clinical practice.
To this end, we report the findings of a retrospective
cohort study performed using a US administrative health-
care claims data to establish the frequency and type of exac-
erbations in 734,114 paediatric patients with asthma. Data
were obtained from the Clinformatics™ DataMart Multiplan
(IMPACT), a product of OptumInsight Life Sciences, Inc.
(Eden Praire, MN), formerly the Integrated Healthcare
Information Services database. The Clinformatics™ Multi-
plan database contains anonymised healthcare claims data,
including information on inpatient and outpatient medical
services and pharmacy dispensing claims, compliant with
the Health Insurance Portability and Accountability Act
(HIPAA) (US Department of Health & Human Services) on
more than 90 million commercially insured patients, pri-
marily from the UnitedHealth Group [16].
In this study, we analysed the annual frequency of paedi-
atric exacerbations in real-world clinical practice and
examined any association of age group or gender with
exacerbation frequency. Additionally, the longitudinal na-
ture of the dataset was utilised to investigate exacerbation
recurrence and seasonal trends in exacerbations.
Methods
Study design
Patients aged > 1–17 years with asthma were identified in
the Clinformatics™ Multiplan administrative healthcare
claims database in the US by the identification of an
outpatient or inpatient claim coded with asthma (ICD9
493.xx) during the period January 1, 2004 and ending on
December 31, 2013; the index date was defined as the date
of the most recently recorded asthma medical code during
the study period that met all inclusion and exclusion
criteria. The study period (2004–2013), included a 10-year
observation period, and data were assessed in a post-hoc
analysis, since the original study period was up to 3 years.
Patients identified in the database were required to have at
least one recorded asthma medication (e.g. short-acting
beta agonist, inhaled corticosteroid [ICS], ICS plus long-
acting beta agonist [LABA], leukotriene receptor antagonist
[LTRA] or omalizumab) dispensing within +/–3 months of
asthma diagnosis, and at least 12 months of data coverage
subsequent to the asthma index date.
Patients were excluded from the cohort if their records
indicated a history of cystic fibrosis or chronic obstruct-
ive pulmonary disease.
Study endpoints
The event of interest in this retrospective cohort
study was asthma exacerbations, defined as treat-
ment with systemic corticosteroids administered both
orally and via injection, asthma-related ED visits, or
asthma-related hospitalisations. Asthma related ED
visits and hospital admissions were determined by
the presence of an asthma primary diagnosis and/or
discharge diagnosis.
Statistical analysis
Data were extracted from the Clinformatics™ Multiplan
database and maintained and analysed using SAS v9.2 soft-
ware (SAS Institute Inc., Cary, NC, USA). All patient-level
data were anonymised before being made available for
analysis in this study and US data collection was compliant
with HIPAA. Therefore, use of these data in clinical re-
search is exempt from Institutional Review Board review.
ICD-9 codes were used to select patients with asthma
and healthcare utilisation associated with asthma. The
subsequent 12-month period was queried for recorded
systemic corticosteroid tablet treatment of 3 or more
days (systemic corticosteroids administered via injec-
tion were not required to have a minimum duration).
ED visits and hospitalisations with an associated
asthma-related diagnosis code were also captured dur-
ing this period. Systemic corticosteroid dispensing
occurring less than 7 days apart was considered a
single event.
Table 1 Chronic inflammatory diseases with ICD-9 codes
included in the sensitivity analysis
Chronic inflammatory disease ICD9 code
Systemic lupus erythematosus (710.0)
Juvenile ankylosing spondylitis (720.0)
Scleroderma (710.1)




Juvenile rheumatoid arthritis (714.3, 714.30, 714.31,
714.32, 714.33)
Juvenile dermatomyositis (710.3)




Sickle cell anaemia (282.6x)
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We assessed the overall incidence and type of
exacerbation, and the impact of patient demographic
factors (age and gender) on exacerbation frequency.
Exacerbation recurrence and the relationship be-
tween use of controller medications (e.g. LTRA,
ICS, ICS/LABA, systemic corticosteroid, omalizu-
mab, theophylline) and exacerbation frequency were
also assessed. A sensitivity analysis was performed
to evaluate the effect of exclusion of patients in the
cohort whose claims history indicated comorbid
chronic inflammatory disease (Table 1). The pres-
ence of a comorbid chronic inflammatory disease
that may have required the use of systemic cortico-
steroids at any time during the patient’s medical
history was defined as having an ICD-9 code as
listed in Table 1.
Table 3 Asthma exacerbation frequency among the study cohort paediatric asthma patients, by gender and age group
Number of exacerbations during 12 month follow-up period Total
0 1 2 3 ≥4
n (%) n (%) n (%) n (%) n (%) N
Overall 481,822 (65.6) 189,457 (25.8) 43,592 (5.9) 12,278 (1.7) 6,965 (1.0) 734,114
Gender
Female 205,789 (67.5) 75,394 (24.7) 16,517 (5.4) 4,530 (1.5) 2,635 (0.9) 304,865
Male 276,033 (64.3) 114,063 (26.6) 27,075 (6.3) 7,748 (1.8) 4,330 (1.0) 429,249
Age groups
0–1 years 25,495 (55.5) 14,078 (30.7) 4,218 (9.2) 1,359 (3.0) 782 (1.7) 45,932
> 1–2 years 24,329 (54.6) 14,176 (31.8) 4,084 (9.2) 1,282 (2.9) 684 (1.5) 44,555
> 2–3 years 25,722 (57.0) 13,904 (30.8) 3,742 (8.3) 1,138 (2.5) 630 (1.4) 45,136
4–12 years 262,219 (66.3) 101,711 (25.7) 22,297 (5.6) 6,077 (1.5) 3,206 (0.8) 395,510
13–17 years 144,057 (71.0) 45,588 (22.5) 9,251 (4.6) 2,422 (1.2) 1,663 (0.8) 202,981
Table 2 Demographic and exacerbation data derived from the study cohort
Characteristics No exacerbations ≥1 exacerbation Total
n Column % n Column % Row % n Column %
Total 481,822 100.0 252,292 100.0 34.4 734,114 100.0
Gender
Male 276,033 57.3 153,216 60.7 35.7 429,249 58.5
Female 205,789 42.7 99,076 39.3 32.5 304,865 41.5
Age at date of asthma diagnosis
≤ 1 year 25,495 5.3 20,437 8.1 44.5 45,932 6.3
> 1–2 years 24,329 5.0 20,226 8.0 45.4 44,555 6.1
> 2–3 years 25,722 5.3 19,414 7.7 43.0 45,136 6.1
4–12 years 262,219 54.4 133,291 52.8 33.7 395,510 53.9
13–17 years 144,057 29.9 58,924 23.4 29.0 202,981 27.6
Asthma index datea
2004 41,964 10.3 17,066 8.9 28.9 59,030 9.8
2005 45,312 11.1 18,947 9.9 29.5 64,259 10.7
2006 51,128 12.6 21,546 11.2 29.6 72,674 12.1
2007 45587 11.2 20,957 10.9 31.5 66,544 11.1
2008 38,942 9.6 18,952 9.9 32.7 57,894 9.7
2009 40,484 10.0 20,025 10.4 33.1 60,509 10.1
2010 38,010 9.4 19,044 9.9 33.4 57,054 9.5
2011 42,088 10.4 19,975 10.4 32.2 62,063 10.4
2012 62,761 15.4 35,703 18.6 36.3 98,464 16.5
aValues are for patients 4–17 years at asthma index date
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Data were interpreted descriptively. Based on pre-
vious analyses of the Clinformatics™ Multiplan da-
tabases, it was determined that the number of
paediatric asthma patients likely to be present in the
database would be sufficient to achieve the aims of
the study.
Results
Overview of patient population and exacerbation data
Data for 734,114 paediatric patients with asthma who
met the criteria for data inclusion were analysed
(Table 2). The overall study population comprised more
males than females (58.5 % vs. 41.5 %); age ranged
from > 1 to 17 years.
In the study cohort, 34.4 % experienced ≥ 1 exacerbation
during the 12-month follow-up period (males 60.7 %;
females 39.3 %). Increasing age was associated with de-
creased frequency of exacerbations and reduced incidence
of exacerbation recurrence (Table 3). The overall mean
exacerbation frequency for patients experiencing ≥ 1 ex-
acerbation during the follow-up period was 1.4 events per
person (standard deviation = 0.9), with a higher incidence
of recurrence observed in the younger age groups com-
pared to the older children and adolescents (Table 2 and
Fig. 1a). The proportion of patients with at least one exacer-
bation during the 12-month follow-up period increased
from 2004 to 2012 (Table 2). No difference in frequency of
recurrent exacerbations by gender was observed (Fig. 1b).
Fig. 1 Exacerbation frequency during the 12-month follow-up period by a age group and b gender
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A sensitivity analysis of the study population excluding
patients with any history of comorbid chronic inflammatory
disease showed that exclusion of these patients (n = 13,036)
did not affect the overall findings, with the overall exacerba-
tion frequency being near identical (1.4 vs. 1.4).
Exacerbation type
Summary statistics on exacerbation type data were
generated (Table 4). Systemic corticosteroid-defined
exacerbations (i.e., outpatient treatment) accounted
for nearly 85.8 % of recorded events. Among the
observed exacerbations, there were a greater propor-
tion of ED visit-defined exacerbations (not precluding
the use of systemic corticosteroids) compared with
hospitalisation-defined exacerbations (11.8 % versus
2.4 %, respectively). Although a greater proportion of
asthma-related hospitalisations were associated with
younger age, there was no variation by gender.
Seasonal distribution of exacerbations
Seasonal variation in exacerbation frequency was analysed
for all exacerbations and by type of exacerbations (Fig. 2).
A trend of seasonality was observed where the exacerba-
tion frequency was the highest in the fall and early winter
and lowest during the month of July. The trend was most
pronounced for systemic corticosteroid-defined exacerba-
tions, though a similar trend can be seen for ED visit-
defined and hospital-defined exacerbations.
Association between controller medication use and
exacerbation frequency
Exacerbation frequency among patients in the cohort
was analysed, overall and by age and gender, according
to whether or not there was evidence that the patient
had been prescribed asthma controller medication at the
asthma index date (Fig. 3). A trend whereby patients
prescribed controller medication at baseline were more
likely to have had ≥ 1 exacerbation during the 12-month
follow-up period was identified; no effect of gender was
seen. Although there was no significant variation in
exacerbation rates between groups defined by asthma
controller use at baseline or gender, a trend towards a
higher rate of exacerbations with younger age was
observed (Table 5). There were very few reports of
exacerbations with omalizumab; 18 males with a mean
(SD) exacerbation frequency of 1.50 (0.86) and 18
females with 1.83 (1.47) exacerbations. As there were so
few cases, these data have not been included in Table 5.
Discussion
This study used a US population-based healthcare claims
database to investigate paediatric exacerbation frequency.
These findings suggest that approximately one-third of
Fig. 2 Asthma exacerbations in paediatric patients with asthma by month, overall and by exacerbation type
Table 4 Asthma patients with≥ 1 exacerbation (n = 252,292) by
first exacerbation type recorded during the study period
Specified type n (%)
Hospitalisation 6,080 (2.4)
Emergency department visit 29,713 (11.8)
Systemic corticosteroida 216,499 (85.8)
aIncludes corticosteroid injection
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paediatric asthma patients (<1–17 years of age) will ex-
perience an exacerbation within a 12-month period, with
a smaller subset of patients (<9 %) experiencing ≥ 2 exac-
erbations. Despite being a small proportion of the overall
population, this patient group with evidence of more
severe asthma could have a disproportionate impact on
overall healthcare burden.
Diagnosis of asthma in children aged ≤ 5 years, and
especially in infants, is a particular challenge [17]. Symp-
toms typically characteristic of asthma, such as wheezing
and cough, are common in this age group and not
necessarily indicative of asthma, and viral infections
such as bronchiolitis can confound asthma diagnosis;
furthermore, diagnostic tests such as spirometry are often
not possible because of the requirement for the patient to
perform voluntary breathing manoeuvres in a reproducible
manner [11]. As only patients with a recorded asthma
diagnosis and at least one asthma medication were included
in the cohort, it is possible that asthma prevalence in this
age group may be misclassified (e.g. under-reported).
It should be noted that, because of limitations of the
available data resource, the definition of asthma exacer-
bations used in this retrospective cohort study differed
from the American Thoracic Society and European
Respiratory Society consensus definition [18]. While we
anticipate that most severe exacerbations (requiring
hospitalisation and/or ED visits) be treated with systemic
corticosteroids and be recorded in the claims database,
moderate or mild exacerbations may not have been fully
captured, specifically those that did not require treat-
ment with a systemic corticosteroid. Nearly 86 % of re-
corded exacerbations were identified through dispensed
systemic corticosteroid and approximately 14 % required
hospitalisation or ED visits (not precluding the use of
systemic corticosteroids). It is unclear why we observed
an increase in exacerbation frequency between 2004 and
2012. The US Centers for Disease Control and Pre-
vention has published data showing that hospitalisa-
tion frequency rates remained unchanged from 2001
to 2009, whereas the prevalence of asthma increased
[19]. These findings suggest that the increased exacer-
bation frequency observed in our study may be attrib-
utable to an increase in oral corticosteroid-defined
exacerbations, rather than an increase in hospitalisa-
tions. Another possible explanation, of which further
exploration may be warranted, is that the increase in
exacerbation frequency may result from incremental
improvements in data completeness (i.e. better recording
of hospitalisations and ED visits and/or improvements in
medication dispensing/prescribing data).
Oral corticosteroids are recommended for the first-
line treatment of acute exacerbations in children [11].
However, the adverse impact of the chronic use of
systemic corticosteroids was assessed recently in a real-
world study of patients with severe asthma. Results from
this assessment showed that there was a dose-dependent
increase in the risk of developing infections, and/or
gastrointestinal and cardiovascular complications in
patients aged > 12 years who received daily systemic
corticosteroids [20]. Although in the present analysis
inclusion of systemic corticosteroid prescription data
enabled exacerbations that did not require hospitalisation
or ED visits to be captured. Systemic corticosteroid use
for reasons other than asthma exacerbation could not be
ruled out, and therefore some spurious exacerbations may
have been recorded. To account for this possibility, a
sensitivity analysis was performed evaluating a subset of
patients without comorbid chronic inflammatory condi-
tions (for which patients may have been prescribed
systemic corticosteroid without having experienced an
asthma exacerbation). This sensitivity analysis did not
Fig. 3 Proportion of patients with ≥ 1 exacerbation during the
12-month follow-up by a age and b gender. *The subset of asthma
patients on controller medications was defined as follows: patients
who had received an asthma controller medication (LTRA, ICS, ICS/
LABA, OCS or injectable steroid, omalizumab, theophylline)
within +/-3 months of the index date
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identify any decrease in the frequency of recorded
asthma exacerbations.
A seasonal pattern of paediatric asthma exacerbations
is well established [21–24]. In particular, a peak in
asthma exacerbations and asthma-related hospitalisa-
tions in September has been widely observed in children
in the Northern Hemisphere [22–25]. Furthermore, a
link between asthma exacerbations and falling tempera-
tures has also been observed [26]. Our data reflect these
previously reported findings, showing a marked increase
in exacerbations from August to September. This au-
tumnal peak coincides with children returning to school
and having a greater exposure to viral infections [24].
There is considerable evidence to support a causal link
between viral respiratory tract infections and asthma
exacerbations in children, with respiratory viruses being
detected in over 80 % of paediatric patients who experi-
ence asthma exacerbations [27–30].
When the current analysis was restricted to the
subset of patients using controller medications at the
asthma index date, the proportion of patients ex-
periencing an exacerbation increased. Consistent with
previously reported findings, this suggests that exacer-
bations occur more frequently in patients who have
evidence of more severe asthma and are, therefore,
more likely to be prescribed ICS, in accordance with
asthma management guidelines and medication label-
ling [11, 31]. By extension, this suggests that if stricter
selection criteria (e.g. excluding patients with mild
asthma, who represent a large proportion of the over-
all asthma population) had been used, the reported
exacerbation frequency may have been greater than
our results suggest. This observation should be inter-
preted in light of the fact that patients were not
stratified by baseline asthma severity, nor does the
methodology used take into account adherence or
compliance to medication or comparison with patients
who were undertreated.
Previously, managed care data from US healthcare
claims databases have been used to investigate exacerba-
tion frequency and associated factors in patients of all
ages [5, 32]. Results from a study of adults with asthma
show that the risk of exacerbation does not appear to
change over time, even with high-intensity treatment,
but the occurrence of previous exacerbations does in-
crease the risk of subsequent events [33]. In this study,
we made use of these data to specifically examine paedi-
atric exacerbation frequency using a retrospective cohort
approach. Our findings indicate that the occurrence of
exacerbations among children diagnosed with asthma is
as high in real-world clinical practice as has been previ-
ously suggested by the smaller-scale studies mentioned
above. Recurrence of exacerbations requiring treatment
with systemic corticosteroid or more intensive inter-
vention is observed in < 10 % of the paediatric asthma
population, and the healthcare burden associated with
childhood asthma is heightened during the fall season.
Although treatment of asthma has improved since 2004
our results suggest a trend towards an increase in exac-
erbations as the proportion of patients with at least one
event, identified in the index date, increased over the
course of the study (28.9 % in 2004 to 36.3 % in 2012).
Table 5 Mean annual exacerbation rate by asthma therapy










0 -1 2017 1.50 (0.89) 5 1.60 (0.89) 490 1.67 (1.07) 3502 1.42 (0.83)
>1 – 2 2036 1.49 (0.89) 10 2.0 (2.0) 1060 1.59 (1.08) 3709 1.37 (0.74)
>2 – 3 2084 1.46 (0.86) 17 1.35 (0.79) 1440 1.56 (1.0) 3289 1.34 (0.77)
4 – 12 11321 1.36 (0.83) 2034 1.42 (0.93) 12209 1.44 (0.89) 20719 1.29 (0.81)
13 – 17 3693 1.35 (0.93) 3227 1.42 (0.93) 5915 1.45 (1.06) 11070 1.39 (1.01)
Overall 0-17 21151 1.40 (0.86) 5293 1.42 (0.93) 21114 1.46 (0.96) 42289 1.34 (0.86)
Males
0–1 4552 1.60 (1.02) 6 2.0 (0.63) 1232 1.68 (1.09) 6112 1.47 (0.89)
>1–2 3950 1.52 (0.94) 22 1.91 (1.06) 2042 1.65 (1.08) 5803 1.42 (0.81)
>2–3 3630 1.48 (0.93) 40 1.93 (1.46) 2446 1.56 (1.02) 5114 1.40 (0.89)
4–12 19133 1.39 (0.84) 3743 1.42 (0.84) 21698 1.45 (0.92) 32895 1.32 (0.84)
13–17 4208 1.32 (0.85) 3777 1.37 (0.91) 21698 1.45 (0.92) 13397 1.35 (0.92)
Overall 0–17 35473 1.43 (0.89) 7588 1.40 (0.88) 34104 1.45 (1.06) 42289 1.34 (0.86)
aincludes nebulized medications
ICS inhaled corticosteroid, LABA long-acting beta agonist, LTRA leukotriene receptor antagonist, OCS oral corticosteroid
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The current findings are relevant as, although there
are some results in the published literature describing
exacerbation frequency in adults with asthma [33], there
are limited data in paediatric patients with asthma iden-
tified in a large healthcare claims database, including a
breakdown of exacerbation frequency by type. Moreover,
the large sample size utilised to quantify the frequency
of asthma exacerbations in this paediatric patient popu-
lation can be considered a strength of the current study.
Conclusions
These findings highlight the potential unmet need in ap-
proximately one-third of paediatric patients with asthma
who experienced an exacerbation. This is particularly
important because paediatric patients are more suscep-
tible to adverse effects associated with the chronic use of
systemic corticosteroids. We propose that a more targeted
treatment approach with particular focus on those who
have a history of recurrent exacerbations, together with
improved treatment engagement of patients and their
parents or guardians, in combination with the prescription
of effective controller medications, could result in mean-
ingful improvements in asthma control in children.
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